Profound Medical Corp
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Arun S. Menawat
- Full Time Employees
- 162
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 2400 Skymark Avenue Mississauga ON Canada L4W 5K5
- IPO Date
- Sep 24, 2014
- Website
- profoundmedical.com
- Similar Companies
- Business
- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) develops and commercializes customizable, incision-free therapies that combine real-time magnetic resonance imaging, thermal ultrasound, robotically-driven ablation and closed-loop temperature feedback control for the radiation-free treatment of diseased tissue, primarily targeting prostate conditions and uterine fibroids; its lead product, TULSA-PRO, provides transurethral ultrasound ablation for localized prostate cancer, radio-recurrent prostate cancer, benign prostatic hyperplasia and palliation in advanced cases, offering customizable whole-gland or partial ablation while preserving functional abilities such as urinary continence and sexual function, with CE mark, Health Canada approval and U.S. FDA 510(k) clearance; it also markets Sonalleve, a MR-HIFU platform for non-invasive treatment of uterine fibroids and bone metastases pain palliation, approved by the China FDA for fibroids and under exploration for abdominal cancers and hyperthermia applications. Founded in 2008 and headquartered in Mississauga, Ontario, Canada, the company operates globally with key commercial activities in North America, Europe and Asia Pacific, serving urologists, oncologists and interventional radiologists through direct sales, partnerships and distribution networks. Recent developments include an exclusive distribution and supply agreement with Getz Healthcare in November 2025 to commercialize TULSA-PRO in Australia and New Zealand, regaining exclusive Canadian distribution rights from Knight Therapeutic via a one-time payment in November 2025, and a strategic partnership between Texas Prostate and Dallas Medical Center to launch a TULSA program expanding Medicare access in the U.S.
Company News
Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days'
Profound Medical Announces Management Change
Profound Medical Launches ‘Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey
Profound Medical Q2 Earnings Call Highlights
Profound Medical (PROF) Q2 Earnings Surpass Estimates
Profound Medical Reports Second Quarter 2026 Financial Results
Robotic Radical Prostatectomy Comes Up ‘Short' in CAPTAIN Trial
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last?
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High?
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
Profound Medical Annual General and Special Meeting of Shareholders Voting Results